About Priothera
Priothera is a company based in Dublin (Ireland) founded in 2020 by Brice Suire and Florent Gros. Priothera has raised $35.47 million across 3 funding rounds from investors including European Investment Bank, Tekla Capital Management and Fountain Healthcare Partners. Priothera offers products and services including Mocravimod and CAR T Cell Therapy. Priothera operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
- Headquarter Dublin, Ireland
- Founders Brice Suire, Florent Gros
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Priothera Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.47 M (USD)
in 3 rounds
-
Latest Funding Round
$1.96 M (USD), Grant
Jun 24, 2025
-
Investors
European Investment Bank
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Priothera
Priothera offers a comprehensive portfolio of products and services, including Mocravimod and CAR T Cell Therapy.
Immune modulator to enhance leukemia treatment outcomes.
Advances curative potential for blood cancer patients.
People of Priothera
Unlock access to complete
Unlock access to complete
Funding Insights of Priothera
Priothera has successfully raised a total of $35.47M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.96 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Priothera
Priothera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Tekla Capital Management and Fountain Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Risk capital is provided to life sciences entrepreneurs.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Priothera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Priothera
Investment portfolio details for Priothera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Priothera
Detailed financials for Priothera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Priothera Comparisons
Peer comparison for Priothera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Priothera
Priothera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
Detailed competitors of Priothera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Priothera
Complete news archive for Priothera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Priothera
Priothera was founded in 2020.
Priothera is headquartered in Dublin, Ireland.
Florent Gros is the current CEO of Priothera. They have also founded this company.
Priothera is a funded company, having raised a total of $35.47M across 3 funding rounds to date.
Priothera was founded in 2020 and is based in Dublin, Ireland. Focus is placed on the biotechnology sector, where therapeutics for hematological malignancies are developed. Operations center on mocravimod, an S1P receptor modulator used as adjunctive immune therapy alongside allogeneic hematopoietic stem cell transplantation. This approach serves as post-remission treatment for acute myeloid leukemia patients. Co-founders include Brice Suire and Florent Gros, who leads as CEO.
Priothera's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
Priothera offers Mocravimod and CAR T Cell Therapy.
Priothera has 5 investors. Key investors include European Investment Bank, Tekla Capital Management, Fountain Healthcare Partners, Healthcap, and Earlybird.